QT Imaging Holdings Inc

Análisis de la acción QT Imaging Holdings Inc (QTI)

$3.090

-0.030 (-0.96%)Al cierre

Loading chart…
High
3.200
Open
3.160
VWAP
3.08
Vol
56.09K
Mkt Cap
Low
2.950
Amount
172.77K
EV/EBITDA, TTM
-2.48

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.

AI analysis of QT Imaging Holdings Inc (QTI)

buy

QT Imaging Holdings Inc appears to be a good buy right now due to its recent 103% revenue growth in Q2 2026, bringing total revenue to $7.4 million, and a current price of $3.09, which is below its historical SMA of $4.982. The company also received FDA approval for enhanced product capabilities, which could drive future sales. However, the main risk is the high debt-to-equity ratio of 680.85%, indicating potential financial instability.

Métricas de valoración

The current forward P/E ratio for QT Imaging Holdings Inc (QTI) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.89
Current EV/EBITDA
-2.48
Sobrevalorada
2.17
Infravalorada
-3.95

Forward P/S

Overvalued
5Y Average P/S
0.15
Current P/S
0.72
Sobrevalorada
0.50
Infravalorada
-0.21

Cronología de eventos

2026-08-12 (ET)

16:30:00

QT Imaging Reports Q2 Revenue of $7.4M, Below Estimates

2026-08-04 (ET)

09:00:00

QT Imaging Appoints New VPs to Advance U.S. Sales Strategy

2026-07-29 (ET)

09:00:00

QT Imaging Appoints Julia Albright as Chief Science Officer

2026-07-28 (ET)

09:00:00

QT Imaging Secures Israeli Health Ministry Registration Until 2028

2026-07-07 (ET)

09:00:00

QT Imaging Successfully Completes FDA Routine Inspection with Zero Observations

Noticias

QTI FAQ — answered by Alphio AI

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).

QT Imaging Holdings Inc appears to be a good buy right now due to its recent 103% revenue growth in Q2 2026, bringing total revenue to $7.4 million, and a current price of $3.09, which is below its historical SMA of $4.982. The company also received FDA approval for enhanced product capabilities, which could drive future sales. However, the main risk is the high debt-to-equity ratio of 680.85%, indicating potential financial instability.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis